Short Communication, Endocrinol Diabetes Res Vol: 9 Issue: 4
Role of the Gut Microbiome in Diabetes: New Approches for Treatment through Dietary and Probiotic Interventions
Received date: 25 July, 2023, Manuscript No. ECDR-23-114262;
Editor assigned date: 28 July, 2023, Pre QC No. ECDR-23-114262 (PQ);
Reviewed date: 04 August, 2023, QC No. ECDR-23-114262;
Revised date: 18 August, 2023, Manuscript No: ECDR-23-114262 (R);
Published date: 25 August, 2023, DOI: 10.35248/2470-7570.100358
Citation: Jameson R (2023) Role of the Gut Microbiome in Diabetes: New Approches for Treatment through Dietary and Probiotic Interventions. Endocrinol Diabetes Res 9:4.
The landscape of diabetes research has been evolving at an accelerated pace, especially in the context of exploring new treatment avenues. One emerging area of interest is the role of the gut microbiome in diabetes management. The gut microbiome consists of trillions of microorganisms, including bacteria, viruses, fungi, and other entities that inhabit our digestive tract. Intriguingly, accumulating evidence suggests that alterations in these microbial communities may not only be implicated in the onset and progression of diabetes but also could provide a new frontier for its treatment .
The gut microbiome is central to various metabolic processes, including nutrient absorption, energy regulation, and immune function. In diabetes, specifically Type 2, a compromised microbiome is often seen, characterized by decreased diversity of gut flora and an imbalance known as dysbiosis. This dysbiosis has been implicated in increasing inflammation, enhancing gut permeability, and contributing to insulin resistance, which is the cornerstone of Type 2 diabetes. Even in Type 1 diabetes, an autoimmune condition, gut microbial imbalances are observed and thought to play a role in disease progression . One of the most direct methods to alter the gut microbiome is through diet. Research shows that a diet high in fiber, fruits, and vegetables promotes a healthier microbial community. High-fiber diets, in particular, feed beneficial bacteria that produce short-chain fatty acids, which have anti-inflammatory properties and may improve insulin sensitivity .
Conversely, diets high in fats and sugars can lead to a proinflammatory state, mediated by the gut microbiome, thereby exacerbating diabetes symptoms. Several clinical trials are underway to better understand the specific dietary changes that could lead to a healthier gut microbiome and improved glycemic control in diabetic patients . Probiotics are another avenue for altering the gut microbiome. These live bacteria and yeasts are similar to the beneficial microorganisms naturally found in the gut. Various studies have demonstrated that the administration of specific probiotic strains can enhance the abundance of beneficial bacteria, reduce inflammation, and even improve glycemic control in diabetes patients .
Prebiotics, unlike probiotics, are non-digestible fibers that serve as food for beneficial gut bacteria. When consumed, prebiotics help increase the population of healthy bacteria in the gut, thereby improving metabolic function and potentially ameliorating diabetes symptoms. Synbiotics are a combination of pre- and probiotics that work synergistically to improve the gut microbiome. While the initial findings are promising, extensive research is still required to standardize these interventions for broader clinical application . For example, the most effective strains of probiotics for diabetes management are still under investigation. The ideal 'dose' of dietary changes, as well as the duration of interventions needed to see measurable changes in glycemic control, is not yet clear .
In conclusion, the role of the gut microbiome in diabetes presents a pathway for future research and treatment strategies . Dietary changes and probiotic supplements offer a non-pharmacological approach to alter the microbiome, potentially reducing diabetes symptoms or even reversing disease progression . As research in this area continues to unfold, it may very well revolutionize our understanding of diabetes and how it is managed .
- Inamo J, Kochi Y, Takeuchi T (2021) Is type 2 diabetes mellitus an inverse risk factor for the development of rheumatoid arthritis?. J Hum Genet 66: 219-223.
- Liu Y, Hazlewood G, Kaplan G, Eksteen B, Barnabe C (2017) Impact of obesity on remission and disease activity in rheumatoid arthritis: A systematic review and meta-analysis. Arthritis Care Res 69:157-165.
- Dubreuil M, Rho Y, Man A, Zhu Y, Zhang Y, et al (2014) Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: A UK population-based cohort study. Rheumatology 53:346-52.
- Pablo P, Maggs F, Carruthers D, Faizal A, Pugh M (2014) AB0279 Incidence of diabetes and effect of etanercept and adalimumab on hba1c over 1 year: Data from a randomised trial in patients with rheumatoid arthritis. Ann Rheum Dis 72:1395.
- Rosenfeld RG (2006) The Pharmacogenomics of Human Growth. J Clin Endocrinol Metab 91:795–796.
- Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V, et al (2004) A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet 36:720–724. [Crossref]
- Zhang L, Hu Y, Yan J, Yang J, Bai G, et al. (2020) Phosphaturic mesenchymal tumor of the occipitocervical region: Report of two rare cases and literature review.
- Savage CR, Zimmer LA (2009) Oncogenic osteomalacia from pterygopalatine fossa mass. J Laryngol Otol 123:1052-1054.
- Tang R, Mao S, Lin H, Ye HB, Li DW, et al. (2020) Surgical treatment and outcomes for sinonasal and skull base phosphaturic mesenchymal tumors. Otolaryngol Head Neck Surg 162:674-682.
- Gresham MS, Shen S, Zhang YJ, Gallagher K (2017) Anterior skull base glomangioma-induced osteomalacia. J Neurol Surg Rep 78:e9-e11.